Expertise in
1
conditions

James D. Cavenagh

Guys And St Thomas' NHS Trust
London, ENG, GB 
Expertise in
1
conditions
Guys And St Thomas' NHS Trust
London, ENG, GB 

Overview

James Cavenagh practices practicing medicine in London, United Kingdom.

Mr. Cavenagh is highly rated in 1 condition, according to our data. His clinical expertise encompasses Multiple Myeloma, Acute Myeloid Leukemia (AML), Leukemia, Paroxysmal Nocturnal Hemoglobinuria (PNH), and Bone Marrow Transplant.

He is actively involved in clinical research, co-authoring 14 peer reviewed articles and participating in 2 clinical trials.

Gender

Male

Locations

Guys and St Thomas' NHS Trust
London, ENG, United Kingdom

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

Carfilzomib/Cyclophosphamide/Dexamethasone with Maintenance Carfilzomib in Untreated Transplant-eligible Patients with Symptomatic MM to Evaluate the Benefit of Upfront ASCT
Carfilzomib/Cyclophosphamide/Dexamethasone with Maintenance Carfilzomib in Untreated Transplant-eligible Patients with Symptomatic MM to Evaluate the Benefit of Upfront ASCT
Enrollment Status: Active_not_recruiting
Publish Date: December 06, 2024
Intervention Type: Procedure, Drug
Study Drug: Consolidation with 4 cycles of CarCyDex
Study Phase: Phase 2
A Phase III, International, Randomized, Controlled Study of Rigosertib Versus Physician's Choice of Treatment in Patients With Myelodysplastic Syndrome After Failure of a Hypomethylating Agent
A Phase III, International, Randomized, Controlled Study of Rigosertib Versus Physician's Choice of Treatment in Patients With Myelodysplastic Syndrome After Failure of a Hypomethylating Agent
Enrollment Status: Terminated
Publish Date: September 26, 2022
Intervention Type: Drug
Study Drug: Rigosertib
Study Phase: Phase 3
View 1 Less Clinical Trial

14 Total Publications

Eltrombopag Added to Standard Immunosuppressive Treatment as Front-Line Therapy for Severe Aplastic Anemia: Long-Term Outcomes of the Phase-3 Randomized Superiority EBMT-SAAWP RACE Study.
Eltrombopag Added to Standard Immunosuppressive Treatment as Front-Line Therapy for Severe Aplastic Anemia: Long-Term Outcomes of the Phase-3 Randomized Superiority EBMT-SAAWP RACE Study.
Journal: American journal of hematology
Published: February 05, 2026

Frequently Asked Questions about James D. Cavenagh

Is James D. Cavenagh a top-rated expert for Multiple Myeloma?

MediFind is an objective health platform that identifies experts based on real-world data. James D. Cavenagh is classified as an Advanced expert for Multiple Myeloma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does James D. Cavenagh participate in research or clinical trials?

Yes. James D. Cavenagh has published 14 articles and abstracts on conditions like Multiple Myeloma. You can view a list of James D. Cavenagh's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Cavenagh's expertise for a condition
ConditionClose
      View All 8 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile